Menu
Recruiting NCT04711746

Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?

No phase Interventional Pulmonary Embolism Hematopoiesis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: blood sample.
Who it may be relevant to
Registry conditions: Pulmonary Embolism, Hematopoiesis. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The clonal hematopoiesis of indetermined prognosis (CHIP) has been described as risk factor for juvenile atherosclerosis. Moreover, some of CHIP genes are responsible of myeloproliferative disorders. Venous thrombosis are frequent in these disorders. The purpose of this project is to determine if CHIP is frequent in unprovoked pulmonary embolism and could be part of the pathophysiology.

Interventions

  • Biological blood sample
    Blood sample withdrawal in order to perform DNA sequencing

Primary outcome measures

  • Variation of CHIP markers between patients groups [Time frame: up to 2 years]

Eligibility criteria

Inclusion criteria

  • For cases : Previous proximal unprovoked pulmonary embolism, negative thrombophilia screening.
  • For control : Previous proximal provoked pulmonary embolism, negative thrombophilia screening.

Exclusion criteria

  • Age superior to 65 years old,
  • Active cancer

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Diagnostic

Study locations

France · 1 center
  • CHU Amiens — Amiens

Identifiers

NCT: NCT04711746 · PI2020_843_0117

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗